# EDGAR Filing Document

**Accession Number:** 0001826434
**File Stem:** 0001826434-25-000007
**Filing Date:** 2025-8
**Character Count:** 14250
**Document Hash:** e96aa1242aa0c8fa159d09fad0f2e076
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001826434-25-000007.hdr.sgml**: 20250827

**ACCESSION NUMBER**: 0001826434-25-000007

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250827

**EFFECTIVENESS DATE**: 20250827

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tri Locum Partners LP
- **CENTRAL INDEX KEY:** 0001826434

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-21000
- **FILM NUMBER:** 251265766

**BUSINESS ADDRESS:**
- **STREET 1:** 287 PARK AVENUE SOUTH, 2ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** 332-232-7373

**MAIL ADDRESS:**
- **STREET 1:** 287 PARK AVENUE SOUTH, 2ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001826434

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Tri Locum Partners LP

**Address:** 287 Park Avenue South, New York, NY 10010

**Telephone number:** 332-232-7373

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-21000

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** 549300X3MQVEBBKNVR31

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                      | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                                                                                                                            | VOTE CATEGORY                |     SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Avadel Pharmaceuticals plc          | G29687103 | 07/30/2024     | To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company.                                                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES | 592699           |                0 | FOR         |                         592699           | FOR                         |  |
| Axsome Therapeutics, Inc.           | 05464T104 | 06/06/2025     | To approve, by non-binding advisory vote, the compensation of our named executive officers.                                                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |  63935           |                0 | FOR         |                          63935           | FOR                         |  |
| Biohaven Ltd.                       | G1110E107 | 05/05/2025     | A non-binding advisory vote on the compensation of the Company's named executive officers.                                                                                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES | 128420           |                0 | AGAINST     |                         128420           | AGAINST                     |  |
| Blueprint Medicines Corporation     | 09627Y109 | 06/18/2025     | Approval of a non-binding advisory vote on the compensation paid to our named executive officers.                                                                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |  37121           |                0 | FOR         |                          37121           | FOR                         |  |
| Evolus, Inc.                        | 30052C107 | 06/05/2025     | Approval of, on an advisory basis, the compensation of Evolus' named executive officers.                                                                                                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |  87596           |                0 | FOR         |                          87596           | FOR                         |  |
| Gilead Sciences, Inc.               | 375558103 | 05/07/2025     | To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.                                                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES | 238481           |                0 | FOR         |                         238481           | FOR                         |  |
| Illumina, Inc.                      | 452327109 | 05/21/2025     | To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement.                                                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |  72482           |                0 | FOR         |                          72482           | FOR                         |  |
| Inspire Medical Systems, Inc.       | 457730109 | 05/01/2025     | Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.                                                                                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |  26750           |                0 | FOR         |                          26750           | FOR                         |  |
| Korro Bio, Inc.                     | 500946108 | 06/11/2025     | Non-Binding Advisory Vote to Approve the Compensation of our Named Executive Officers.                                                                                                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |  49897           |                0 | FOR         |                          49897           | FOR                         |  |
| Korro Bio, Inc.                     | 500946108 | 06/11/2025     | Non-Binding Advisory Vote on the Frequency of Future Non-Binding Advisory Votes to Approve the Compensation of our Named Executive Officers                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |  49897           |                0 | 1 YEAR      |                          49897           | FOR                         |  |
| Madrigal Pharmaceuticals, Inc.      | 558868105 | 06/20/2025     | Advisory vote to approve executive compensation.                                                                                                                                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |  24931           |                0 | FOR         |                          24931           | FOR                         |  |
| Madrigal Pharmaceuticals, Inc.      | 558868105 | 06/20/2025     | Advisory vote to approve the frequency of future advisory votes to approve executive compensation.                                                                                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |  24931           |                0 | 1 YEAR      |                          24931           | FOR                         |  |
| Nuvalent, Inc.                      | 670703107 | 06/18/2025     | To approve, on an advisory basis, the compensation paid to our named executive officers.                                                                                                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |  29470           |                0 | FOR         |                          29470           | FOR                         |  |
| Praxis Precision Medicines, Inc.    | 74006W207 | 06/26/2025     | To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2025 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion. | SECTION 14A SAY-ON-PAY VOTES |  64555           |                0 | AGAINST     |                          64555           | AGAINST                     |  |
| Summit Therapeutics Inc.            | 86627T108 | 06/12/2025     | Approval, by a non-binding advisory vote, of the compensation of our named executive officers.                                                                                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |  18510           |                0 | FOR         |                          18510           | FOR                         |  |
| Teva Pharmaceutical Industries Ltd. | 881624209 | 06/05/2025     | To approve, on a non-binding advisory basis, the compensation for Teva's named Executive Officers                                                                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |      1.41243e+06 |                0 | FOR         |                              1.41243e+06 | FOR                         |  |
| The Cigna Group                     | 125523100 | 04/23/2025     | Advisory approval of executive compensation                                                                                                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |  36977           |                0 | FOR         |                          36977           | FOR                         |  |
| Vera Therapeutics, Inc.             | 92337R101 | 05/14/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.                                                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES | 143042           |                0 | FOR         |                         143042           | FOR                         |  |
| Vera Therapeutics, Inc.             | 92337R101 | 05/14/2025     | To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES | 143042           |                0 | 1 YEAR      |                         143042           | FOR                         |  |
| Verona Pharma plc                   | 925050106 | 04/24/2025     | To Approve, On An Advisory (Non-Binding) Basis, The Compensation Of The Company's Named Executive Officers.                                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES | 154269           |                0 | AGAINST     |                         154269           | AGAINST                     |  |

## N-PX: Signature Block

**Reporting Person:** Tri Locum Partners LP

**By (Signature):** Christabel Syham

**By (Printed Signature):** Christabel Syham

**By (Title):** Chief Business Officer and Chief Compliance Officer

**Date:** 08/27/2025